表阿霉素+紫杉醇+卡铂治疗宫颈癌的疗效及对血清CA125、AFP、SCCA水平的影响  

Curative Effect of Epirubicin Combined with Paclitaxel and Carboplatin on Cervical Cancer and its Influences on Serum CA125,AFP and SCCA Levels

作　　者：董巧兰 赵会菊 姜燕 DONG Qiaolan;ZHAO Huiju;JIANG Yan(Xinzheng People's Hospital,Xinzheng,451100)

机构地区：[1]河南省新郑市人民医院,451100

出　　处：《实用癌症杂志》2021年第6期1018-1020,1032,共4页The Practical Journal of Cancer

摘　　要：目的探讨表阿霉素+紫杉醇+卡铂治疗宫颈癌的疗效及对血清糖类抗原125(CA125)、甲胎蛋白(AFP)、鳞状细胞癌抗原(SCCA)水平的影响。方法将宫颈癌患者102例随机分为研究组和对照组,各51例,对照组给予紫杉醇+卡铂治疗,研究组给予表阿霉素+紫杉醇+卡铂治疗,观察比较两组治疗后的临床疗效,记录比较两组治疗前后血清癌胚抗原(CEA)、CA125、AFP、SCCA以及外周血T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)T细胞)计数水平,记录两组治疗期间不良反应的发生情况。结果经治疗后,研究组疾病总控制率及外周血CD3^(+)、CD4^(+)、CD8^(+)T细胞计数明显高于对照组(P<0.05),血清CEA、CA125、AFP、SCCA水平均明显低于对照组(P<0.05)。两组治疗期间不良反应无明显差异(P>0.05)。结论表阿霉素+紫杉醇+卡铂能提高宫颈癌患者的临床疗效,降低血清肿瘤标志物水平,提高免疫功能,且具有较高的用药安全性。Objective To explore the curative effect of epirubicin combined with paclitaxel and carboplatin on cervical cancer and its influences on levels of serum carbohydrate antigen 125(CA125),alpha-fetoprotein(AFP)and squamous cell carcinoma antigen(SCCA).Methods A total of 102 patients with cervical cancer were randomly divided into the study group and the control group,51 cases in each group.The control group was treated with paclitaxel and carboplatin,while study group was treated with epirubicin,paclitaxel and carboplatin.The clinical curative effect after treatment was observed and compared between the 2 groups.The serum carcinoembryonic antigen(CEA),CA125,AFP and SCCA,as well as peripheral blood T lymphocyte subsets(CD3^(+)、CD4^(+)、CD8^(+)T cells)counts in both groups were recorded and compared.The occurrence of adverse reactions in both groups during treatment was recorded.Results After treatment,the total control rate of disease,counts of peripheral blood CD3^(+)、CD4^(+)、CD8^(+)T cells were significantly higher in the study group than the control group(P<0.05),while levels of serum CEA,CA125,AFP and SCCA were significantly lower in the study group(P<0.05).There was no significant difference in adverse reactions during treatment between the 2 groups(P>0.05).Conclusion Epirubicin combined with paclitaxel and carboplatin can improve the clinical curative effect on patients with cervical cancer,reduce levels of serum tumor markers,and improve immune function,with relatively higher medication safety.

关 键 词：表阿霉素 紫杉醇 卡铂 宫颈癌 血清糖类抗原125 甲胎蛋白 鳞状细胞癌抗原 临床疗效 

分 类 号：R737.33[医药卫生—肿瘤]